Evidence map›Paper›PMID 37391427›Full record

ArticleNature communications2023

High body temperature increases gut microbiota-dependent host resistance to influenza A virus and SARS-CoV-2 infection.

Minami Nagai, Miyu Moriyama, Chiharu Ishii, Hirotake Mori, Hikaru Watanabe, Taku Nakahara, Takuji Yamada, Dai Ishikawa, Takamasa Ishikawa, Akiyoshi Hirayama and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Minami Nagai *Division of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Miyu Moriyama *Division of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-0310-9047
Chiharu Ishii *Institute for Advanced Biosciences, Keio University, Yamagata, Japan.
Hirotake MoriDepartment of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan.ORCID 0000-0002-7988-5758
Hikaru WatanabeMetagen Therapeutics, Inc., Yamagata, Japan.
Taku NakaharaMetagen Therapeutics, Inc., Yamagata, Japan.
Takuji YamadaMetagen Therapeutics, Inc., Yamagata, Japan.ORCID 0000-0002-9622-1849
Dai IshikawaMetagen Therapeutics, Inc., Yamagata, Japan.
Takamasa IshikawaInstitute for Advanced Biosciences, Keio University, Yamagata, Japan.
Akiyoshi HirayamaInstitute for Advanced Biosciences, Keio University, Yamagata, Japan.ORCID 0000-0002-0440-6820
Ikuo KimuraLaboratory of Molecular Neurobiology, Graduate School of Biostudies, Kyoto University, Kyoto, Japan.ORCID 0000-0001-8778-145X
Akihito NagaharaLaboratory for Regenerative Microbiology, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Toshio NaitoDepartment of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan. naito@juntendo.ac.jp.
Shinji FukudaInstitute for Advanced Biosciences, Keio University, Yamagata, Japan. sfukuda@sfc.keio.ac.jp.ORCID 0000-0001-5161-9880
Takeshi IchinoheDivision of Viral Infection, Department of Infectious Disease Control, International Research Center for Infectious Diseases, Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ichinohe@ims.u-tokyo.ac.jp.ORCID 0000-0002-6376-2841
Juntendo University · JPKeio University · JPNational Institute of Infectious Diseases · JPKyoto University · JPTokyo Institute of Technology · JPUniversity of Tsukuba · JP

Funding

National Metabolomics Data Repository - nextgen Metabolomics WorkbenchU2CDK119886 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2018 to 2021
$12.7M
NIDDK NIH HHS U2C DK119886
6 · The paper itself

Abstract

Fever is a common symptom of influenza and coronavirus disease 2019 (COVID-19), yet its physiological role in host resistance to viral infection remains less clear. Here, we demonstrate that exposure of mice to the high ambient temperature of 36 °C increases host resistance to viral pathogens including influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). High heat-exposed mice increase basal body temperature over 38 °C to enable more bile acids production in a gut microbiota-dependent manner. The gut microbiota-derived deoxycholic acid (DCA) and its plasma membrane-bound receptor Takeda G-protein-coupled receptor 5 (TGR5) signaling increase host resistance to influenza virus infection by suppressing virus replication and neutrophil-dependent tissue damage. Furthermore, the DCA and its nuclear farnesoid X receptor (FXR) agonist protect Syrian hamsters from lethal SARS-CoV-2 infection. Moreover, we demonstrate that certain bile acids are reduced in the plasma of COVID-19 patients who develop moderate I/II disease compared with the minor severity of illness group. These findings implicate a mechanism by which virus-induced high fever increases host resistance to influenza virus and SARS-CoV-2 in a gut microbiota-dependent manner.

Indexed as

COVID-19Gastrointestinal MicrobiomeInfluenza A virusInfluenza, HumanAnimalsBile Acids and SaltsBody TemperatureCricetinaeFeverHumansMesocricetusMiceSARS-CoV-2Bile Acids and Salts

Identifiers

PMID37391427
PMCPMC10313692
OpenAlexW4382776858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.